CM-109

N/A

Report date: 2026/03/19 17:15:56

Base Information

Drug NameCM-109

Drug Alias NameCM-109

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-MUC17Anti-CD3

TargetsMucin-17T cell surface glycoprotein CD3

Therapy Area/IndicationsStomach NeoplasmsEsophageal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesGuangzhou Excelmab Inc

China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Excelmab Inc

Inactive CompaniesN/A

Active IndicationsStomach NeoplasmsEsophageal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A